NCT03047135View on ClinicalTrials.gov

Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

March 1, 2017

Primary Completion Date

May 24, 2023

Study Completion Date

May 1, 2026

Conditions
Prostate
Interventions
DRUG

Olaparib

Olaparib will be dispensed to patients on Day 1 and every 28 days thereafter until the patient completes the study, withdraws from the study or closure of the study.

Trial Locations (4)

15212

Allegheny Cancer Center, Pittsburgh

19107

Thomas Jefferson University, Philadelphia

21231

Johns Hopkins Hospital, Baltimore

68198

University of Nebraska Medical Center, Omaha

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER